Physician profile
Norin Ali
NPI 1487266748
$2,995.62
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.41 · 2021: $334 · 2022: $849 · 2023: $854 · 2024: $756 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.07 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,014.08 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $654.70 | 2020-2024 | Cequa |
| Kala Pharmaceuticals, INC. | $285.36 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $209.15 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $190.59 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $178.35 | 2023 | Miebo, Vyzulta, Alrex |
| Dompe US, INC. | $156.95 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $70.56 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $61.47 | 2021-2023 | |
| Alcon Vision LLC | $56.34 | 2021 | |
| Allergan, INC. | $47.54 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $30.17 | 2022 | |
| Heidelberg Engineering, INC. | $24.76 | 2023 | Spectralis |
| Harrow Eye, LLC | $15.60 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norin Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.